Lopez-Guillermo, A, Canales, MA, Dlouhy, I, Mercadal, S, Briones, J, Garcia-Sancho, AM, Sancho, JM, Moraleda, JM, Terol, MJ, Salar, A, Palomera, L, Gardella, S, Jarque, I, Ferrer, S, Bargay, J, Lopez, A, Panizo, C, Muntanola, A, Montalban, C, Conde, E, Hernandez, MT, Soler, A, Marco, JAG, Deben, G, Marin, J, Tomas, JF. A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. LEUKEMIA & LYMPHOMA. 2022; 63(1)DOI:10.1080/10428194.2021.1971216. PMID:34459702. IF:2.600(Q3/7D).

Pinana, JL, Lopez-Corral, L, Martino, R, Montoro, J, Vazquez, L, Perez, A, Martin-Martin, G, Facal-Malvar, A, Ferrer, E, Pascual, MJ, Sanz-Linares, G, Gago, B, Sanchez-Salinas, A, Villalon, L, Conesa-Garcia, V, Olave, MT, Lopez-Jimenez, J, Marcos-Corrales, S, Garcia-Blazquez, M, Garcia-Gutierrez, V, Hernandez-Rivas, JA, Saus, A, Espigado, I, Alonso, C, Hernani, R, Solano, C, Ferrer-Lores, B, Guerreiro, M, Ruiz-Garcia, M, Munoz-Bellido, JL, Navarro, D, Cedillo, A, Sureda, A. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. AMERICAN JOURNAL OF HEMATOLOGY. 2022; 97(1)DOI:10.1002/ajh.26385. PMID:34695229. IF:12.800(Q1/1D).

Kanda, J, Hayashi, H, Ruggeri, A, Kimura, F, Volt, F, Takahashi, S, Kako, S, Tozatto-Maio, K, Yanada, M, Sanz, G, Uchida, N, Angelucci, E, Kato, S, Mohty, M, Forcade, E, Tanaka, M, Sierra, J, Ohta, T, Saccardi, R, Fukuda, T, Ichinohe, T, Kimura, T, Rocha, V, Okamoto, S, Nagler, A, Atsuta, Y, Gluckman, E. The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. BONE MARROW TRANSPLANTATION. 2022; 57(1)DOI:10.1038/s41409-021-01479-4. PMID:34635798. IF:4.800(Q1/2D).

Rucker, FG, Du, L, Luck, TJ, Benner, A, Krzykalla, J, Gathmann, I, Voso, MT, Amadori, S, Prior, TW, Brandwein, JM, Appelbaum, FR, Medeiros, BC, Tallman, MS, Savoie, L, Sierra, J, Pallaud, C, Sanz, MA, Jansen, JH, Niederwieser, D, Fischer, T, Ehninger, G, Heuser, M, Ganser, A, Bullinger, L, Larson, RA, Bloomfield, CD, Stone, RM, Dohner, H, Thiede, C, Dohner, K. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. LEUKEMIA. 2022; 36(1)DOI:10.1038/s41375-021-01323-0. PMID:34316017. IF:11.400(Q1/1D).

Pallares, V, Unzueta, U, Falgas, A, Avino, A, Nunez, Y, Garcia-Leon, A, Sanchez-Garcia, L, Serna, N, Gallardo, A, Alba-Castellon, L, Alamo, P, Sierra, J, Cedo, L, Eritja, R, Villaverde, A, Vazquez, E, Casanova, I, Mangues, R. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. BIOMATERIALS. 2022; 280DOI:10.1016/j.biomaterials.2021.121258. PMID:34847435. IF:14.000(Q1/1D).

Moreno, C, Mora, A. MRD in CLL: some answers, many questions. BLOOD. 2021; 138(26)DOI:10.1182/blood.2021013435. PMID:34967869. IF:25.669(Q1/1D).

Jimenez, AMJ, De Lima, M, Komanduri, KV, Wang, TP, Zhang, MJ, Chen, KR, Abdel-Azim, H, Abid, MB, Aljurf, M, Alkhateeb, H, Assal, A, Bacher, U, Baron, F, Battiwalla, M, Beitinjaneh, A, Bejanyan, N, Bhatt, VR, Byrne, M, Cahn, JY, Cairo, M, Castillo, P, Copelan, E, DeFilipp, Z, Perez, MAD, Elsawy, M, Gale, RP, George, B, Grunwald, MR, Hildebrandt, GC, Hogan, WJ, Kanakry, CG, Kansagra, A, Kharfan-Dabaja, MA, Khera, N, Krem, MM, Lazaryan, A, Maakaron, J, Martino, R, McGuirk, J, Michelis, FV, Milone, G, Mishra, A, Murthy, HS, Mussetti, A, Nathan, S, Nishihori, T, Olsson, RF, Palmisiano, N, Patel, S, Saad, A, Seo, S, Sharma, A, Solh, M, Verdonck, LF, Wirk, B, Yared, JA, Litzow, M, Kebriaei, P, Hourigan, CS, Saber, W, Weisdorf, D. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. BONE MARROW TRANSPLANTATION. 2021; 56(12)DOI:10.1038/s41409-021-01450-3. PMID:34584240. IF:5.174(Q2/3D).

Granell, M, Senin, A, Barata, A, Cibeira, MT, Gironella, M, Lopez-Pardo, J, Motllo, C, Garcia-Guinon, A, Ben-Azaiz, R, Abella, E, Soler, A, Canet, M, Marti, JM, Martino, R, Sierra, J, de Larrea, CF, Oriol, A, Rosinol, L. Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma. BONE MARROW TRANSPLANTATION. 2021; 56(12)DOI:10.1038/s41409-021-01429-0. PMID:34404917. IF:5.174(Q2/3D).

Diefenbach, C, Kahl, BS, McMillan, A, Briones, J, Banerjee, L, Cordoba, R, Miall, F, Burke, JM, Hirata, J, Jiang, YW, Paulson, JN, Chang, YM, Musick, L, Abrisqueta, P. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Lancet Haematology. 2021; 8(12)DOI:10.1016/S2352-3026(21)00311-2. PMID:34826412. IF:30.153(Q1/1D).

Albiol, N, Arguello-Tomas, M, Moreno, C. The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. CURRENT OPINION IN ONCOLOGY. 2021; 33(6)DOI:10.1097/CCO.0000000000000791. PMID:34474439. IF:3.915(Q3/6D).

Moreno, C, Munoz, C, Terol, MJ, Hernandez-Rivas, JA, Villanueva, M. Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2021; 40(1)DOI:10.1186/s13046-021-02115-1. PMID:34654437. IF:12.658(Q1/1D).

Einsele, H, Briones, J, Ciceri, F, Cadenas, IG, Falkenburg, F, Bolanos, N, Heemskerk, HMM, Houot, R, Hudecek, M, Locatelli, F, Morgan, K, Morris, EC, O'Dwyer, M, Sierra, JG, van den Brink, M, van de Loosdrecht, AA. The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies. Hemasphere. 2021; 5(10)DOI:10.1097/HS9.0000000000000642. PMID:34522844. IF:8.300(Q1/2D).

Genesca, E, Morgades, M, Gonzalez-Gil, C, Fuster-Tormo, F, Haferlach, C, Meggendorfer, M, Montesinos, P, Barba, P, Gil, C, Coll, R, Moreno, MJ, Martinez-Carballeira, D, Garcia-Cadenas, I, Vives, S, Ribera, J, Gonzalez-Campos, J, Diaz-Beya, M, Mercadal, S, Artola, MT, Cladera, A, Tormo, M, Bermudez, A, Vall-llovera, F, Martinez-Sanchez, P, Amigo, ML, Monsalvo, S, Novo, A, Cervera, M, Garcia-Guinon, A, Ciudad, J, Cervera, J, Hernandez-Rivas, JM, Granada, I, Haferlach, T, Orfao, A, Sole, F, Ribera, JM. Adverse prognostic impact of complex karyotype (>= 3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). LEUKEMIA RESEARCH. 2021; 109DOI:10.1016/j.leukres.2021.106612. PMID:34139642. IF:3.715(Q3/6D).

Ribera, JM, Morgades, M, Coll, R, Barba, P, Lopez-Lorenzo, JL, Montesinos, P, Foncillas, MA, Cabrero, M, Gomez-Centurion, I, Morales, MD, Varela, MR, Herrera, P, Garcia-Cadenas, I, Calbacho, M, Torrent, A, Maluquer, C, Calabuig, M, Garcia-Guinon, A, Bautista, G, Llorente, L, Gil, C, Artola, MT, Gonzalez-Campos, J, Fernandez-Moreno, A, Barez, A, Gimenez-Perez, T, Bergua, J, Sanchez-Sanchez, MJ, Mateos, MC, Pinana, JL. Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain. Clinical Lymphoma Myeloma & Leukemia. 2021; 21(10)DOI:10.1016/j.clml.2021.06.024. PMID:34376375. IF:2.822(Q3/8D).

Ribera, JM, Morgades, M, Genesca, E, Chapchap, EC, Montesinos, P, Acuna-Cruz, E, Gil, C, Garcia-Cadenas, I, Barba, P, Gonzalez-Campos, J, de Llano, MPQ, Torrent, A, Ribera, J, Granada, I, Bernal, T, Diaz-Beya, M, Amigo, ML, Coll, R, Tormo, M, Vall-llovera, F, Gomez-Centurion, I, Sanchez-Sanchez, MJ, Soria, B, Cladera, A, Artola, MT, Garcia-Guinon, A, Gimenez-Conca, A, Amador, ML, Martinez-Sanchez, P, Algarra, JL, Vidal, MJ, Alonso, N, Maluquer, C, Llorente, L, Garcia-Boyero, R, Ciudad, J, Feliu, E, Orfao, A. Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. HEMATOLOGICAL ONCOLOGY. 2021; 39(4)DOI:10.1002/hon.2910. PMID:34405901. IF:4.850(Q2/5D).

Ljungman, P, de la Camara, R, Mikulska, M, Tridello, G, Aguado, B, Al Zahrani, M, Apperley, J, Berceanu, A, Bofarull, RM, Calbacho, M, Ciceri, F, Lopez-Corral, L, Crippa, C, Fox, ML, Grassi, A, Jimenez, MJ, Demir, SK, Kwon, M, Llamas, CV, Lorenzo, JLL, Mielke, S, Orchard, K, Porras, RP, Vallisa, D, Xhaard, A, Knelange, NS, Cedillo, A, Kroger, N, Pinana, JL, Styczynski, J. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. LEUKEMIA. 2021; 35(10)DOI:10.1038/s41375-021-01302-5. PMID:34079042. IF:12.897(Q1/1D).

Esquirol, A, Pascual, MJ, Kwon, M, Perez, A, Parody, R, Ferra, C, Cadenas, IG, Herruzo, B, Dorado, N, Hernani, R, Sanchez-Ortega, I, Torrent, A, Sierra, J, Martino, R. Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. BONE MARROW TRANSPLANTATION. 2021; 56(10)DOI:10.1038/s41409-021-01328-4. PMID:34059802. IF:5.174(Q2/3D).

Sierra, J, Nomdedeu, JF. CEBPA bZip mutations: just a single shot. BLOOD. 2021; 138(13)DOI:10.1182/blood.2021011263. PMID:34591099. IF:25.669(Q1/1D).

Dohner, H, Malcovati, L, Ossenkoppele, GJ, Hochhaus, A, Vannucchi, AM, Bullinger, L, Cervantes, F, Craddock, C, de Witte, T, Dohner, K, Dombret, H, Fenaux, P, Geissler, J, Germing, U, Guilhot, F, Harrison, C, Hellstrom-Lindberg, E, Passamonti, F, Sierra, J, Skoda, R, Wierzbowska, A. The EHA Research Roadmap: Malignant Myeloid Diseases. Hemasphere. 2021; 5(9)DOI:10.1097/HS9.0000000000000635. PMID:34476345. IF:8.300(Q1/2D).

Larson, RA, Mandrekar, SJ, Huebner, LJ, Sanford, B, Laumann, K, Geyer, S, Bloomfield, CD, Thiede, C, Prior, TW, Dohner, K, Marcucci, G, Voso, MT, Klisovic, RB, Galinsky, I, Wei, AH, Sierra, J, Sanz, MA, Brandwein, JM, de Witte, T, Niederwieser, D, Appelbaum, FR, Medeiros, BC, Tallman, MS, Krauter, J, Schlenk, RF, Ganser, A, Serve, H, Ehninger, G, Amadori, S, Gathmann, I, Dohner, H, Stone, RM. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. LEUKEMIA. 2021; 35(9)DOI:10.1038/s41375-021-01179-4. PMID:33654204. IF:12.897(Q1/1D).

Kharfan-Dabaja, MA, Kumar, A, Ayala, E, Aljurf, M, Nishihori, T, Marsh, R, Burroughs, LM, Majhail, N, Al-Homsi, AS, Al-Kadhimi, ZS, Bar, M, Bertaina, A, Boelens, JJ, Champlin, R, Chaudhury, S, DeFilipp, Z, Dholaria, B, El-Jawahri, A, Fanning, S, Fraint, E, Gergis, U, Giralt, S, Hamilton, BK, Hashmi, SK, Horn, B, Inamoto, Y, Jacobsohn, DA, Jain, T, Johnston, L, Kanate, AS, Kansagra, A, Kassim, A, Kean, LS, Kitko, CL, Knight-Perry, J, Kurtzberg, J, Liu, H, MacMillan, ML, Mahmoudjafari, Z, Mielcarek, M, Mohty, M, Nagler, A, Nemecek, E, Olson, TS, Oran, B, Perales, MA, Prockop, SE, Pulsipher, MA, Pusic, I, Riches, ML, Rodriguez, C, Romee, R, Rondon, G, Saad, A, Shah, N, Shaw, PJ, Shenoy, S, Sierra, J, Talano, J, Verneris, MR, Veys, P, Wagner, JE, Savani, BN, Hamadani, M, Carpenter, PA. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation And Cellular Therapy. 2021; 27(8)DOI:10.1016/j.jtct.2021.04.007. PMID:34304802. IF:(Q/D).

Bueno, F, Solano, C, Vazquez, L, Gimenez, E, de la Camara, R, Albert, E, Rovira, M, Espigado, I, Calvo, CM, Lopez-Jimenez, J, Suarez-Lledo, M, Chinea, A, Esquirol, A, Perez, A, Bermudez, A, Saldana, R, Heras, I, Gonzalez-Huerta, AJ, Torrado, T, Batlle, M, Jimenez, S, Vallejo, C, Barba, P, Cuesta, MA, Duarte, R, Pinana, JL, Navarro, D. Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. Transplant Infectious Disease. 2021; 23(4)DOI:10.1111/tid.13627. PMID:33908148. IF:2.867(Q3/6D).

Bento, L, Gutierrez, A, Novelli, S, Montoro, J, Pinana, JL, Lopez-Corral, L, Cabrero, M, Martin-Sancho, A, Gutierrez-Garcia, G, Ortiz-Moscovich, M, Bastos-Oreiro, M, Dorado, N, Perez, A, Hernani, R, Ferra, C, Parody, R, Garcia-Cadenas, I, Herrera, P, Rodriguez, G, Rodriguez, N, Martin, C, Yanez, L, Zanabili, J, Varela, MR, Lopez-Godino, O, Heras, I, Espanol, I, Martinez, C, Perez-Simon, JA, Solano, C, Sureda, A, Sierra, J, Sampol, A, Caballero, D. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. BONE MARROW TRANSPLANTATION. 2021; 56(8)DOI:10.1038/s41409-021-01264-3. PMID:33767400. IF:5.174(Q2/3D).

Pallares, V, Nunez, Y, Sanchez-Garcia, L, Falgas, A, Serna, N, Unzueta, U, Gallardo, A, Alba-Castellon, L, Alamo, P, Sierra, J, Villaverde, A, Vazquez, E, Casanova, I, Mangues, R. Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4. JOURNAL OF CONTROLLED RELEASE. 2021; 335DOI:10.1016/j.jconrel.2021.05.014. PMID:34004204. IF:11.467(Q1/1D).

Albiol, N, Moreno, C. Autoimmune Cytopenia in CLL Prognosis and Management in the Era of Targeted Therapies. CANCER JOURNAL. 2021; 27(4)DOI:10.1097/PPO.0000000000000537. PMID:34398555. IF:2.074(Q4/9D).

Esquirol, A, Pascual, MJ, Garcia-Cadenas, I, Herruzo, B, Ferra, C, Perez, A, Torio, A, Torrent, A, Cuesta, M, Martino, R, Sierra, J. Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide. Transplantation And Cellular Therapy. 2021; 27(7)DOI:10.1016/j.jtct.2021.03.021. PMID:33775908. IF:(Q/D).

Greil, R, Tedeschi, A, Moreno, C, Anz, B, Larratt, L, Simkovic, M, Gill, D, Gribben, JG, Flinn, IW, Wang, ZY, Cheung, LWK, Nguyen, AN, Zhou, C, Styles, L, Demirkan, F. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. ANNALS OF HEMATOLOGY. 2021; 100(7)DOI:10.1007/s00277-021-04536-6. PMID:34018029. IF:4.030(Q2/5D).

Ribera, JM, Garcia, O, Buendia-Urena, B, Terol, MJ, Vicent, A, Vall-Llovera, F, Bergua, J, Garcia-Cadenas, I, Esteve, J, Ribera, J, Acuna-Cruz, E, Herrera, P, Hernandez-Rivas, JM, Abrisqueta, P, Gonzalez-Campos, J, Rodriguez, C, Bastos-Oreiro, M, Genesca, E, Caminos, N, de Llano, MPQ, Cladera, A, Sancho, JM. Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. LEUKEMIA & LYMPHOMA. 2022; 63(8)DOI:10.1080/10428194.2022.2053531. PMID:35343365. IF:2.600(Q3/7D).

Lopez, S, Martinez-Perez, A, Rodriguez-Rius, A, Vinuela, A, Brown, AA, Martin-Fernandez, L, Vilalta, N, Arus, M, Panousis, NI, Buil, A, Sabater-Lleal, M, Souto, JC, Dermitzakis, ET, Soria, JM. Integrated GWAS and Gene Expression Suggest ORM1 as a Potential Regulator of Plasma Levels of Cell-Free DNA and Thrombosis Risk. THROMBOSIS AND HAEMOSTASIS. 2022; 122(06)DOI:10.1055/s-0041-1742169. PMID:35272364. IF:6.700(Q1/2D).

Bazarbachi, A, Boumendil, A, Finel, H, Khvedelidze, I, Romejko-Jarosinska, J, Tanase, A, Akhtar, S, Ben Othman, T, Ma'koseh, M, Afanasyev, B, Cheikh, J, Briones, J, Gulbas, Z, Hamladji, RM, Elverdi, T, Blaise, D, Martinez, C, Alma, E, Halaburda, K, Sousa, AB, Glass, B, Robinson, S, Montoto, S, Sureda, A. The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. LEUKEMIA. 2022; 36(6)DOI:10.1038/s41375-022-01563-8. PMID:35414657. IF:11.400(Q1/1D).

Mercadal, S, Alana, M, Barcelo, MI, Bruixola, G, Lopez-Pereira, P, Bobillo, S, Dlouhy, I, Agud, RC, Molina, EG, Martinez, P, Cacabelos, P, Muntanola, A, Garcia-Catalan, G, Sancho, JM, Campos, I, Lado, T, Salar, A, Caballero, AC, Sole-Rodriguez, M, Velasco, R. Ocular involvement in patients with primary central-nervous-system lymphoma: Analysis of a multicentre study in Spain. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 197(6)DOI:10.1111/bjh.18148. PMID:35307813. IF:6.500(Q1/3D).

Hernandez-Boluda, JC, Pereira, A, Zinger, N, Gras, L, Martino, R, Nikolousis, E, Finke, J, Chinea, A, Rambaldi, A, Robin, M, Saccardi, R, Natale, A, Snowden, JA, Tsirigotis, P, Vallejo, C, Wulf, G, Xicoy, B, Russo, D, Maertens, J, Daguindau, E, Lenhoff, S, Hayden, P, Czerw, T, McLornan, DP, Yakoub-Agha, I. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT (vol 57, pg 416, 2022). BONE MARROW TRANSPLANTATION. 2022; 57(6)DOI:10.1038/s41409-022-01652-3. PMID:35361897. IF:4.800(Q1/2D).

Onida, F, Sbianchi, G, Radujkovic, A, Sockel, K, Kroger, N, Sierra, J, Socie, G, Cornelissen, J, Poire, X, Raida, L, Bourhis, JH, Finke, J, Passweg, J, Salmenniemi, U, Schouten, HC, Beguin, Y, Martin, S, Deconinck, E, Ganser, A, Zver, S, Lioure, B, Rohini, R, Koster, L, Hayden, P, Iacobelli, S, Robin, M, Yakoub-Agha, I. Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. BONE MARROW TRANSPLANTATION. 2022; 57(6)DOI:10.1038/s41409-021-01555-9. PMID:35352038. IF:4.800(Q1/2D).

González-Muñoza C, Briones J, Sang Park H, García-Planella E. Marginal zone lymphoma under anti-TNF treatment in Crohn disease. Gastroenterologia y Hepatologia. 2022; 45(5)DOI:10.1016/j.gastrohep.2021.05.010. PMID:34118314. IF:1.900(Q4/10D).

Serna, N, Pallares, V, Unzueta, U, Garcia-Leon, A, Volta-Duran, E, Sanchez-Chardi, A, Parlade, E, Rueda, A, Casanova, I, Falgas, A, Alba-Castellon, L, Sierra, J, Villaverde, A, Vazquez, E, Mangues, R. Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery. JOURNAL OF CONTROLLED RELEASE. 2022; 343DOI:10.1016/j.jconrel.2022.01.017. PMID:35051493. IF:10.800(Q1/1D).

Bataller, A, Garrido, A, Guijarro, F, Onate, G, Diaz-Beya, M, Arnan, M, Tormo, M, Vives, S, de Llano, MPQ, Coll, R, Gallardo, D, Vall-Llovera, F, Escoda, L, Garcia-Guinon, A, Salamero, O, Sampol, A, Merchan, BM, Bargay, J, Castano-Diez, S, Esteban, D, Oliver-Caldes, A, Rivero, A, Mozas, P, Lopez-Guerra, M, Pratcorona, M, Zamora, L, Costa, D, Rozman, M, Nomdedeu, JF, Colomer, D, Brunet, S, Sierra, J, Esteve, J. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Advances. 2022; 6(4)DOI:10.1182/bloodadvances.2021005585. PMID:34911079. IF:7.500(Q1/2D).

Pinana, JL, Garcia-Sanz, R, Martino, R, Garcia-Rao, M, Martin-Martin, GA, Risco-Galvez, I, Tormo, M, Martinez-Barranco, P, Marcos-Corrales, S, Calabuig, M, Conesa, V, Teruel, A, Ruiz-Perez, S, Solano, C, Navarro, D, Cedillo, A, Sureda, A. Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2021006326. PMID:34905620. IF:7.500(Q1/2D).

Onate, G, Bataller, A, Garrido, A, Hoyos, M, Arnan, M, Vives, S, Coll, R, Tormo, M, Sampol, A, Escoda, L, Salamero, O, Garcia, A, Bargay, J, Aljarilla, A, Nomdedeu, JF, Esteve, J, Sierra, J, Pratcorona, M. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2020004136. PMID:34516636. IF:7.500(Q1/2D).

Menghrajani, K, Gomez-Arteaga, A, Madero-Marroquin, R, Zhang, MJ, Bo-Subait, K, Sanchez, J, Wang, HL, Aljurf, M, Assal, A, Bacher, VU, Badawy, SM, Bejanyan, N, Bhatt, VR, Bredeson, C, Byrne, M, Castillo, P, Cerny, J, Chhabra, S, Ciurea, SO, DeFilipp, Z, Farhadfar, N, Gadalla, S, Gale, RP, Ganguly, S, Gowda, L, Grunwald, MR, Hashmi, S, Hildebrandt, G, Kanakry, CG, Kansagra, A, Khimani, F, Krem, M, Lazarus, H, Liu, HT, Martino, R, Michelis, FV, Nathan, S, Nishihori, T, Olsson, R, Reshef, R, Rizzieri, D, Rowe, JM, Savani, BN, Seo, S, Sharma, A, Solh, M, Ustun, C, Verdonck, LF, Hourigan, C, Sandmaier, B, Litzow, M, Kebriaei, P, Weisdorf, D, Zhang, YM, Tallman, MS, Saber, W. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2021004881. PMID:34551064. IF:7.500(Q1/2D).

Rule, S, Barreto, WG, Briones, J, Carella, AM, Casasnovas, O, Pocock, C, Wendtner, CM, Zaja, F, Robson, S, MacGregor, L, Tschopp, RR, Nick, S, Dreyling, M. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase Ill MabCute study. HAEMATOLOGICA. 2022; 107(2)DOI:10.3324/haematol.2020.274803. PMID:34134469. IF:10.100(Q1/2D).